Is Sera Prognostics, Inc. (SERA) a Buy, Sell, or Hold?
Sera Prognostics, Inc.
NASDAQ:SERA
$1.98 USD
$0.06 (3.12%)
- Volume
- 52.26K
- Average Volume
- 49.83K
- Market Capitalization
- $75.62M
- P/E Ratio
- -3.05
- Dividend Yield
- 0.00%
- Price Target
- $6.00
- Year High
- $3.95
- Year Low
- $1.56
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.12
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Zhenya Lindgardt |
| Industry | Medical - Diagnostics & Research |
| Sector | Healthcare |
| Current Symbol | SERA |
| CUSIP | 81749D107 |
| CIK | 0001534969 |
| Web | https://seraprognostics.com |
| Phone | 801 990 0520 |
| Currency | USD |
| Employees | 63 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.04 |
| Payout Ratio | 0.00 |
| Current Ratio | 2.12 |
| Quick Ratio | 2.12 |
| Cash Ratio | 0.18 |
Sales & Book Value
| Annual Sales | $81000 |
| Price / Sales | 1326.63 |
| Cash Flow | -0.55 |
| Price / Cash Flow | -2.74 |
| Price / Book | 1.47 |
Price Target and Rating
| Average Stock Price Forecast | $6.00 |
| High Stock Price Forecast | $6.00 |
| Low Stock Price Forecast | $6.00 |
| Forecast Upside/Downside | -67.00% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 5 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-0.67 |
| Trailing P/E Ratio | -3.05 |
| PEG Ratio | -0.08 |
| P/E Growth | -0.08 |
| Net Income | $-31.93M |
| Net Margin | -56385.96% |
| Pretax Margin | -56385.96% |
| Return on Equity | -41.02% |
| Return on Assets | -34.36% |
Financials Score
| AltmanZ Score | -3.85 |
| Piotroski Score | 2.00 |
| Working Capital | 26.31M |
| Total Assets | 93.54M |
| Ebit | -32.13M |
| Market Cap | 75.24M |
| Total Liabilities | 25.92M |
Poll Results
About Sera Prognostics, Inc. (NASDAQ:SERA) Stock
Sera Prognostics, Inc. is a women's health diagnostics firm that focuses on creating, advancing, and bringing to market biomarker tests aimed at improving pregnancy results. Their primary product, the PreTRM test, is a blood-based biomarker assay specifically designed to predict the likelihood of spontaneous preterm birth in singleton pregnancies where no symptoms are yet present. Additionally, the company is cultivating a portfolio of potential tests for various other pregnancy-related conditions, such as preeclampsia, predicting time-to-birth at a molecular level, gestational diabetes mellitus, restricted fetal growth, stillbirth, and postpartum depression. Established in 2008, the organization's main operations are based in Salt Lake City, Utah. ...
2026-07-09 16:05:00
-- Study Highlights Screening Efficiency and Potential Cost Savings in a Large Underserved Population -- SALT LAKE CITY, July 9, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information, today announced publication of a new subgroup analysis from the PRIME randomized controlled trial. The analysis demonstrated that PreTRM® Test-guided care in first-time pregnancies significantly improved neonatal outcomes, including a 22% reduction in neonatal intensive care unit (NICU) admissions.
SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF MARK CAPONE TO ITS BOARD OF DIRECTORS
2026-06-30 16:05:00
SALT LAKE CITY, June 30, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Mark Capone will join its Board of Directors, effective July 1, 2026. Mr. Capone is a seasoned healthcare executive with more than 40 years of leadership experience across the diagnostics and life sciences sectors, including extensive service on private and public company boards and committees.
SERA PROGNOSTICS COLLABORATES ON ARPA-H AWARD TO ADVANCE POINT-OF-CARE DIAGNOSTIC FOR SAFER BIRTH
2026-06-24 16:05:00
SALT LAKE CITY, June 24, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information, today announced its participation in a multi-institutional research program that was awarded up to $10.4 million by the Advanced Research Projects Agency for Health (ARPA-H) to develop a novel point-of-care diagnostic test designed to improve the safety of labor and delivery. The award, part of ARPA-H's Making Obstetrics Care Smart (MOCS) program, supports a collaboration led by researchers at the University of California San Diego (UC San Diego), alongside Sera Prognostics and Allegro MicroSystems.
2026-06-23 16:05:00
--Aligns With Growing Focus on Early Identification and Management of Preterm Birth Risk-- SALT LAKE CITY, June 23, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information, today acknowledged recent legislative action in Illinois aimed at expanding access to evidence-based approaches for identifying and managing the risk of preterm birth among pregnant individuals. The legislation amends the Illinois Public Aid Code to require the state's medical assistance program (Medicaid) to provide coverage and reimbursement for prescribed proteomic blood tests that are used to identify and manage the risk of spontaneous preterm birth.
All You Need to Know About Sera Prognostics (SERA) Rating Upgrade to Buy
2026-06-19 13:01:11
Sera Prognostics (SERA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
SERA PROGNOSTICS ANNOUNCES BOARD TRANSITION
2026-06-01 16:05:00
SALT LAKE CITY, June 1, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Jeff Elliott has notified the Company of his intention to step down from its Board of Directors, effective June 4, 2026, and that he will not stand for re-election at the Company's upcoming Annual Meeting of Shareholders. Mr. Elliott has served on Sera's Board since March 2025, providing strategic guidance and leadership during a period of growth and development for the Company.
Sera Prognostics (SERA) Loses 27% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
2026-05-14 10:35:19
Sera Prognostics (SERA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Sera Prognostics, Inc. (SERA) Q1 2026 Earnings Call Transcript
2026-05-07 02:41:14
Sera Prognostics, Inc. (SERA) Q1 2026 Earnings Call Transcript
Frequently Asked Questions
-
What is the current Sera Prognostics, Inc. (SERA) stock price?
-
Sera Prognostics, Inc.(NASDAQ:SERA) stock price is $1.98 in the last trading session. During the trading session, SERA stock reached the peak price of $3.95 while $1.56 was the lowest point it dropped to. The percentage change in SERA stock occurred in the recent session was 3.12% while the dollar amount for the price change in SERA stock was $0.06.
-
SERA's industry and sector of operation?
-
The NASDAQ listed SERA is part of Medical - Diagnostics & Research industry that operates in the broader Healthcare sector.
-
Who are the executives of SERA?
-
Austin Aerts | Chief Financial Officer
Robert G. Harrison | Chief Information Officer
Chuck Hyde | Head of Market Access
Lee Anderson | Chief Commercial Officer
Jennifer Zibuda | Head of Investor Relations -
How many employees does SERA have?
-
Number of SERA employees currently stands at 63. SERA operates from 2749 East Parleys Way, Salt Lake City, UT 84109, US.
-
Link for SERA official website?
-
Official Website of SERA is: https://seraprognostics.com
-
How do I contact SERA?
-
SERA could be contacted at phone #801 990 0520 and can also be accessed through its website. SERA operates from 2749 East Parleys Way, Salt Lake City, UT 84109, US.
-
How many shares of SERA are traded daily?
-
The average number of SERA shares traded daily for last 3 months was 49.83K.
-
What is the market cap of SERA currently?
-
The market value of SERA currently stands at $75.62M with its latest stock price at $1.98